P&G Health reports Rs 31.80 crore gain from Worli office sale

Procter & Gamble Health Limited booked a Rs 31.80 crore exceptional gain after selling its Worli office premises for Rs 33.34 crore in the quarter ended June 30, 2026. P&G Health recorded a Rs 1.54 crore carrying amount for the property at sale, while six-month investing activities generated Rs 31.73 crore of net cash.

What did P&G Health receive for the Worli office?

P&G Health received Rs 33.34 crore for the Worli office property sold during the quarter ended June 30, 2026. Its carrying amount at the sale date was Rs 1.54 crore, resulting in a Rs 31.80 crore gain that P&G Health classified as an exceptional item in its financial results.

The disposal gain was not included in revenue from operations. P&G Health reported it separately between profit before exceptional items and tax and profit before tax, while identifying pharmaceuticals as its single primary reportable segment under Indian Accounting Standard 108, or Ind AS 108. The filing therefore provides no separate property segment result.

The exceptional gain equals the difference between the stated sale consideration and carrying amount. The six-month cash-flow statement separately reports Rs 33.64 crore of proceeds from disposal of property, plant and equipment and assets held for sale, compared with Rs 0.09 crore in the corresponding 2025 period. P&G Health does not provide a separate reconciliation between the broader proceeds line and the Worli office consideration.

How did the Worli sale affect P&G Health's profit?

P&G Health reported June-quarter profit before tax of Rs 129.12 crore, including the Rs 31.80 crore exceptional gain. Profit before exceptional items and tax was Rs 97.32 crore in that quarter, showing that the office disposal accounted for the difference between the two reported pre-tax measures.

For the six months ended September 30, 2026, P&G Health reported profit before tax of Rs 279.17 crore, up from Rs 207.83 crore in the corresponding six months of 2025. Profit before exceptional items and tax increased to Rs 247.37 crore from Rs 207.13 crore, while the Rs 31.80 crore gain was the only exceptional item shown for the 2026 half year.

Net profit for the 2026 half year was Rs 207.02 crore, compared with Rs 154.72 crore a year earlier. Basic and diluted earnings per share after exceptional items were Rs 125.09 for the six months ended September 30, 2026, compared with Rs 105.94 before exceptional items. The difference reflects the after-tax effect of the reported exceptional item.

How did the sale change P&G Health's cash flows?

P&G Health generated Rs 31.73 crore of net cash from investing activities in the six months ended September 30, 2026, compared with Rs 1.41 crore in the corresponding 2025 period. The increase coincided with Rs 33.64 crore of disposal proceeds, which were substantially above the prior-year amount of Rs 0.09 crore.

Investing inflows also included Rs 2.29 crore of rental income and Rs 5.48 crore of interest received. Against those inflows, P&G Health spent Rs 9.68 crore on purchase and construction of property, plant and equipment and capital work-in-progress, compared with Rs 5.99 crore in the corresponding six months of 2025.

P&G Health ended September 30, 2026 with cash and cash equivalents of Rs 322.86 crore, up from Rs 177.24 crore at March 31, 2026. Net cash and cash equivalents increased by Rs 145.62 crore during the half year, compared with an increase of Rs 97.29 crore in the prior-year period.

Operating activities generated Rs 190.86 crore of cash in the 2026 half year, compared with Rs 172.23 crore a year earlier. Financing activities used Rs 76.97 crore, including a Rs 74.70 crore dividend payment and Rs 2.27 crore of lease-liability payments. These operating and financing flows, together with investing inflows, produced the reported increase in cash.

What do P&G Health's underlying results and balance sheet show?

P&G Health reported revenue from operations of Rs 746.20 crore for the six months ended September 30, 2026, compared with Rs 663.66 crore in the corresponding 2025 period. September-quarter revenue was Rs 382.49 crore, above Rs 363.71 crore in the June 2026 quarter and Rs 324.92 crore in the September 2025 quarter.

Total expenses were Rs 504.60 crore in the 2026 half year, compared with Rs 469.51 crore a year earlier. The 2026 amount included Rs 152.00 crore of materials consumed, Rs 56.00 crore of purchases of stock-in-trade and Rs 114.16 crore of employee benefits expense. P&G Health does not provide product-level expense data because pharmaceuticals is its sole primary reportable segment.

Assets held for sale were nil at September 30, 2026, compared with Rs 1.56 crore at March 31, 2026. Property, plant and equipment rose to Rs 93.13 crore from Rs 90.97 crore, while total assets increased to Rs 1,014.59 crore from Rs 841.35 crore over the same period.

The Board approved the unaudited results on November 2, 2026, after review by the Audit Committee. P&G Health's statutory auditor conducted a limited review and stated that it does not provide an audit opinion; the company also reported no subsidiary, associate or joint venture as of September 30, 2026.

Conclusion

P&G Health's Worli office sale produced a Rs 31.80 crore exceptional gain from Rs 33.34 crore of consideration against a Rs 1.54 crore carrying amount. The transaction lifted reported six-month profit before tax to Rs 279.17 crore and was included within a period in which net investing cash inflow reached Rs 31.73 crore.

The next results after September 30, 2026 will show how P&G Health's revenue, operating cash flow and capital spending develop without a comparable Rs 31.80 crore exceptional gain. The filing discloses no further asset-sale plan, disposal target or scheduled property transaction after the June 2026 sale.